IRIS UniCatt

Tortora, Giampaolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.116
AS - Asia 7.615
EU - Europa 5.336
SA - Sud America 1.640
Continente sconosciuto - Info sul continente non disponibili 417
AF - Africa 224
OC - Oceania 40
Totale 25.388
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.744
SG - Singapore 3.219
IT - Italia 1.658
CN - Cina 1.406
BR - Brasile 1.349
VN - Vietnam 1.010
SE - Svezia 917
DE - Germania 574
FR - Francia 546
IN - India 465
BD - Bangladesh 308
GB - Regno Unito 297
IE - Irlanda 241
FI - Finlandia 229
PL - Polonia 221
HK - Hong Kong 215
ID - Indonesia 214
JP - Giappone 200
CA - Canada 187
NL - Olanda 128
RU - Federazione Russa 123
AR - Argentina 106
MX - Messico 101
IQ - Iraq 87
KR - Corea 80
TR - Turchia 76
ES - Italia 72
AT - Austria 68
ZA - Sudafrica 67
EC - Ecuador 62
UA - Ucraina 46
PK - Pakistan 45
CI - Costa d'Avorio 42
IR - Iran 37
SA - Arabia Saudita 37
AU - Australia 34
CO - Colombia 31
BE - Belgio 30
UZ - Uzbekistan 30
CZ - Repubblica Ceca 29
VE - Venezuela 28
PH - Filippine 27
LT - Lituania 23
JO - Giordania 21
CH - Svizzera 20
CL - Cile 20
EG - Egitto 20
KE - Kenya 19
MA - Marocco 19
AE - Emirati Arabi Uniti 16
JM - Giamaica 15
RO - Romania 15
IL - Israele 14
DZ - Algeria 13
PY - Paraguay 13
TW - Taiwan 13
CR - Costa Rica 12
MY - Malesia 12
TN - Tunisia 12
AZ - Azerbaigian 11
GR - Grecia 11
PT - Portogallo 11
UY - Uruguay 11
KZ - Kazakistan 10
PE - Perù 10
TT - Trinidad e Tobago 10
AL - Albania 9
BO - Bolivia 9
HU - Ungheria 9
NP - Nepal 9
TH - Thailandia 9
BG - Bulgaria 8
HN - Honduras 8
LV - Lettonia 8
BY - Bielorussia 7
LB - Libano 7
NI - Nicaragua 7
RS - Serbia 7
CY - Cipro 6
DO - Repubblica Dominicana 6
NZ - Nuova Zelanda 6
PA - Panama 6
BB - Barbados 5
ET - Etiopia 5
LU - Lussemburgo 5
NG - Nigeria 5
SN - Senegal 5
GE - Georgia 4
GT - Guatemala 4
MD - Moldavia 4
MM - Myanmar 4
PS - Palestinian Territory 4
BA - Bosnia-Erzegovina 3
BJ - Benin 3
DK - Danimarca 3
EU - Europa 3
HR - Croazia 3
OM - Oman 3
PR - Porto Rico 3
SI - Slovenia 3
Totale 24.927
Salva come PNG Salva come JPEG
Città #
Singapore 1.890
Ashburn 1.592
San Jose 1.076
Chandler 685
Rome 453
Ho Chi Minh City 346
Beijing 334
New York 294
Los Angeles 267
Hanoi 259
Dublin 234
Hyderabad 232
Hefei 222
Milan 210
Hong Kong 198
Warsaw 198
Lauterbourg 194
Council Bluffs 192
Tokyo 189
The Dalles 174
Frankfurt am Main 168
Fairfield 167
Jakarta 161
Chicago 159
São Paulo 141
Munich 133
Helsinki 131
Houston 114
Wilmington 110
Princeton 104
Dallas 98
Boston 96
Seattle 92
Santa Clara 91
Boardman 86
St Louis 81
San Mateo 76
Seoul 75
Atlanta 73
Buffalo 73
Orem 71
London 68
Moscow 66
Kent 64
Denver 60
Woodbridge 59
Nuremberg 57
Marseille 56
Cambridge 54
Brooklyn 52
Cattolica 50
Toronto 50
Turku 50
Da Nang 49
Montreal 47
Phoenix 47
Paris 46
Chennai 45
Lappeenranta 45
Abidjan 42
Düsseldorf 42
Johannesburg 41
Stockholm 41
Ann Arbor 40
Haiphong 40
Mexico City 39
Vienna 39
Rio de Janeiro 37
Amsterdam 36
Bremen 33
North Bergen 33
Baghdad 31
Naples 31
Poplar 31
Curitiba 30
Brussels 28
Manchester 28
Washington 28
Salt Lake City 26
Shanghai 26
Tashkent 26
Dhaka 25
Mumbai 25
Matera 24
Nanjing 24
Bexley 23
Dearborn 23
Guangzhou 23
Guayaquil 23
Augusta 22
Belo Horizonte 22
Hải Dương 22
Amman 21
Florence 21
Goiânia 21
Falkenstein 20
Memphis 20
Porto Alegre 20
Brno 19
Campinas 19
Totale 13.669
Salva come PNG Salva come JPEG
Nome #
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection 618
Pembrolizumab as first-line treatment for metastatic uveal melanoma 353
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 351
A digital solution to support the activities: Multidisciplinary Tumor Board process and impact analysis 338
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 329
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer 318
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go 308
Preoperative low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical outcomes in pancreatic cancer patients undergoing surgery: A systematic review and meta-analysis. 288
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 273
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations 255
Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment 232
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 228
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms 227
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 213
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 201
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center 200
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis 197
Gut microbiome, big data and machine learning to promote precision medicine for cancer 195
Personalised Psychological Care in Hospitals: An Organisational Model of Integrated, Patient- and Staff-Centred Services (2019-2024) 191
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 190
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 188
An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer 187
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial 183
Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review 182
Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: A single-center experience 176
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study 176
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 174
Contemporary Analysis of cardiac Tamponade Etiologies, Treatments, and Outcomes: the CATEO Study 170
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 170
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 169
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 169
Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients 165
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 163
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 162
Management of single pulmonary metastases from colorectal cancer: State of the art 162
Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center 160
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 159
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 159
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 157
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making 156
Body composition changes in gastric cancer patients during preoperative flot therapy: Preliminary results of an italian cohort study 156
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 156
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 155
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients 154
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study 153
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 153
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies 152
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 152
Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives 149
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 149
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 149
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 148
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 147
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 146
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives 140
Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. 140
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 140
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma 138
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC) 138
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 138
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 137
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors 137
An IT Platform Supporting Rectal Cancer Tumor Board Activities: Implementation Process and Impact Analysis 136
Conjunctival melanoma: Genetic and epigenetic insights of a distinct type of melanoma 135
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 135
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer 133
Novel epigenetic eight-gene signature predictive of poor prognosis and msi-like phenotype in human metastatic colorectal carcinomas 133
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers 132
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 132
Skin cancer triage and management during COVID-19 pandemic. 132
Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: A systematic review 132
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 132
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center 131
Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials 130
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy? 129
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 129
Biomarkers of response to advanced prostate cancer therapy 129
Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study) 127
Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new? 126
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial 126
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 126
Prognostic factors affecting survival after pulmonary resection of metastatic renal cell carcinoma: A multicenter experience 126
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response 124
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer 123
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 123
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 123
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 123
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics 123
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 122
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 122
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers 122
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients 121
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 120
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer 120
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions 120
Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis 120
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations 119
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma 119
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 118
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 118
Totale 16.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022933 0 40 26 111 44 38 19 134 50 35 225 211
2022/20232.290 327 288 166 313 127 253 139 164 227 82 100 104
2023/20242.118 59 321 81 88 85 201 366 321 45 82 185 284
2024/20254.517 96 84 319 158 273 153 269 154 579 660 906 866
2025/202612.636 1.414 507 824 1.760 1.944 567 1.914 654 824 782 655 791
2026/20271.659 504 1.155 0 0 0 0 0 0 0 0 0 0
Totale 25.388